A Phase 1 Pilot Study of the Subcutaneous (s.c.) Route to Facilitate the Administration of RRx-001

Stopped early · Phase 1

Conditions studied: Malignant Solid Tumor, Lymphomas

In brief

To investigate the dosage of RRx-001 by the subcutaneous route.

Key facts

Study ID

NCT02096341

Run by

EpicentRx, Inc.

People needed

2

Starts

2014-04-01

Expected to finish

2016-01-01

Last updated by the study team

2016-01-21

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• At least 18 years old.
• ECOG (performance) status of 0, 1 or 2.
• Histologically or cytologically confirmed primary or metastatic advanced solid tumors or lymphoma. Subjects with curative treatment options are not eligible for the protocol.
• No active ongoing cancer treatment (except for prostate cancer subjects receiving luteinizing hormone-releasing hormone (LHRH) agonists and anti-androgens such as; Flutamide, Dutasteride, and Finasteride).
• Adequate organ and bone marrow function.
• Male and female subjects of childbearing potential must agree to use contraception.

You may not qualify if…

• Pregnant or breast-feeding.
• Use of anti-coagulant therapy.

Where it is running

• Sarah Cannon Research Institute — Nashville, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.